GTS Securities’s Legend Biotech LEGN Stock Holding History

GTS Securities’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000	Closed	-$202K	–	4243
2023 Q3	$202K	Buy	+3,000	New	+$208K	﹤0.01%	3404

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

GTS Securities's LEGN Position: Q2 2025 in Review

GTS Securities sold out of Legend Biotech (LEGN) in Q2 2025, closing a stake of 8,041 shares — an estimated $273K sold.

GTS Securities first reported a position in LEGN in Q1 2025 and held it in 1 quarter. The position peaked at $273K in Q1 2025. 210 funds tracked by Wall St. Rank hold LEGN as of Q2 2025.

GTS Securities reported no remaining Legend Biotech position as of Q2 2025 after selling out during the quarter.
GTS Securities sold 8,041 Legend Biotech shares in Q2 2025, an estimated $273K.
GTS Securities first reported a position in Legend Biotech in Q1 2025 and held it in 1 quarter.
GTS Securities's Legend Biotech position peaked at $273K in Q1 2025.
210 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.